Africa's goal of increasing intra-Africa-produced vaccines is crucial in developing a self-sufficient health environment for its people. However, the continent is still heavily reliant on external vaccine sources, with Africa contributing only 0.1% of the global vaccine production, despite recording the highest number of deaths from infectious diseases. Dr. Ogwell, the current acting Director of Africa CDC reiterates “If we can strengthen public health institutions to be better prepared to respond to disease outbreaks, more lives could be saved.” Despite these efforts, some bottlenecks prevent these goals from being achieved. This article explores some of the hindrances to achieving vaccine production independence in Africa and the steps that need to be taken.

The high capital cost required to set up infrastructure for large-scale production is one of the most significant challenges hindering Africa's efforts toward vaccine manufacturing. Other bottlenecks include complex regulatory systems, intellectual property barriers, and supply chain issues. However, public-private collaborations can be critical in the growth of Africa's vaccine manufacturing business. Governments and private sector stakeholders can cooperate to address these issues by offering funding and incentives for vaccine production, streamlining regulatory procedures, funding education and training initiatives, enhancing infrastructure and logistics, and fostering technology transfer and knowledge sharing.

In order to develop the biomanufacturing sector in Africa, significant research and development are needed. Governments can establish incentives such as tax breaks, subsidies, and intellectual property protection to encourage private sector investment in R&D. Additionally, research institutions should be grown, collaborative research encouraged, and funds provided for R&D. Formulation of regulations that support private sector involvement in R&D can also aid the growth of the biomanufacturing sector.

Creating local supply chains is essential to guarantee vaccine distribution on schedule. To further support the growth of local manufacturing capacity, issues around intellectual property and technology transfer must also be addressed. Furthermore, robust regulatory structures and policies must be created to ensure the safety and effectiveness of vaccines made locally.

Africa's journey toward vaccine production independence has been slow, and the COVID-19 pandemic has highlighted the urgent need for Africa to accelerate its vaccine manufacturing capabilities. However, progress is being made with the African Union's African Vaccine Acquisition Trust initiative and several vaccine manufacturing facilities coming up in various countries, both public and privately owned. By addressing the bottlenecks in the vaccine production process, governments, private sector stakeholders, and research institutions can work together to increase Africa's vaccine production capabilities, leading to a more self-sufficient health environment for its people.

Hurry up! Join the Medical Internship 3.0 at MedBound!